期刊
BREAST CANCER RESEARCH
卷 12, 期 6, 页码 -出版社
BMC
DOI: 10.1186/bcr2768
关键词
-
类别
资金
- AstraZeneca
- Novartis
- Pfizer
- Sanofi-Aventis
- Roche
- Schering
- Amgen
- Eli Lilly
- GlaxoSmithKline
- Wyeth
- Novartis Pharmaceuticals
Treatment options for women with early-stage breast cancer have never been better, and the addition of bisphosphonates to adjuvant therapy is a valuable new tool capable of substantially improving clinical outcomes for these women. Several recent studies demonstrated that the anticancer activity of bisphosphonates is not limited to bone, and can translate into a reduction in disease recurrence, including reductions in locoregional and distant metastases. In addition, bisphosphonates maintain bone health during adjuvant therapy; this may be especially important for women who are at high risk for fracture.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据